| __timestamp | BioCryst Pharmaceuticals, Inc. | Novartis AG |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 17345000000 |
| Thursday, January 1, 2015 | 1896000 | 17404000000 |
| Friday, January 1, 2016 | 2699000 | 17520000000 |
| Sunday, January 1, 2017 | 1702000 | 17175000000 |
| Monday, January 1, 2018 | 471000 | 18407000000 |
| Tuesday, January 1, 2019 | 4101000 | 14425000000 |
| Wednesday, January 1, 2020 | 1676000 | 15121000000 |
| Friday, January 1, 2021 | 7264000 | 15867000000 |
| Saturday, January 1, 2022 | 6594000 | 15486000000 |
| Sunday, January 1, 2023 | 4661000 | 12472000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. This chart highlights the cost of revenue trends for Novartis AG and BioCryst Pharmaceuticals, Inc. over the past decade. Novartis, a global leader, consistently reported high costs, peaking in 2018 with a 5% increase from the previous year. In contrast, BioCryst, a smaller player, showed more volatility, with costs surging by over 300% in 2021 compared to 2014. This disparity underscores the scale and operational differences between large and small pharmaceutical companies. While Novartis's costs reflect its expansive operations, BioCryst's fluctuations may indicate strategic shifts or market challenges. As the industry faces new challenges, these trends offer insights into how companies manage their financial strategies.
Novartis AG vs Sanofi: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Novartis AG and Bristol-Myers Squibb Company's Expenses
Cost of Revenue Comparison: Novartis AG vs Regeneron Pharmaceuticals, Inc.
Novartis AG vs Biogen Inc.: Efficiency in Cost of Revenue Explored
Novartis AG vs Jazz Pharmaceuticals plc: Efficiency in Cost of Revenue Explored
Novartis AG vs PTC Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Pfizer Inc. vs BioCryst Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Catalent, Inc. and BioCryst Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: Grifols, S.A. vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for MorphoSys AG and BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. vs Evotec SE: Efficiency in Cost of Revenue Explored